Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Bücher
Zeitschriften
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
MTZ-Fachkongress

Antriebe und Energiesysteme von morgen


Austausch von Automobil- und Energiewirtschaft

Am 14./15. Mai geht es in Chemnitz um die Mobilitätswende durch Elektro- und Wasserstofffahrzeuge.
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Understanding Bioeconomy Systems: Integrating Economic, Organisational and Policy Concepts Kapitel lesen Erstes Kapitel lesen

2020 | OriginalPaper | Buchkapitel

18. Conjugated Recombinant Proteins as Emerging New Drugs

verfasst von : Nasir Mahmood, Sarah Bushra Nasir, Kathleen Hefferon

Erschienen in: Bioeconomy for Sustainable Development

Verlag: Springer Singapore

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Conjugation combines protein domains to achieve new functionalities in therapeutic drugs by utilizing their functional and structural versatility creating highly diverse macromolecules. Several human recombinant protein drugs are being used for the treatment of different diseases. However to improve these recombinant protein drugs’ bioavailability and to incorporate different new features in the single-protein drug, sortase-mediated conjugation is a promising technology. The sortase A enzyme from Staphylococcus aureus can link any two proteins if one contains N-terminal triglycine (GGG) motif and second contains C-terminal LPXTG motif. In this new protein recombinant drugs can be developed. It is estimated that in the future, conventional recombinant protein drugs will be modified with the help of conjugation technology, and new recombinant drugs will be available with further enhancement of recombinant drugs business worldwide.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Jetzt informieren
Vorheriges Kapitel The Global Economic Impact of Neurodegenerative Diseases: Opportunities and Challenges
Nächstes Kapitel Economic Importance of Medicinal Plants in Asian Countries
Literatur
Abuchowski A, van Es T, Palczuk N, Davis F (1977) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 252:3578–3581
Aggarwal S (2011) What’s fueling the biotech engine. 2010 to 2011. Nat Biotech 29:1083–1089CrossRef
Alconcel SN, Baas AS, Maynard HD (2011) FDA-approved poly (ethylene glycol)–protein conjugate drugs. Polym Chem 2(7):1442–1448CrossRef
Antos JM, Chew GL, Guimaraes CP, Yoder NC, Grotenbreg GM, Popp MW, Ploegh HL (2009) Site-specific N- and C-terminal labeling of a single polypeptide using sortases of different specificity. J Am Chem Soc 131(31):10800–10801CrossRef
Armstrong JK, Wenby RB, Meiselman HJ, Fisher TC (2003) In vivo survival of poly(ethylene glycol)-coated red blood cells in the rabbit. Blood 102:94A
Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, Garratty G (2007) Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110:103–111. PubMed: 17516438CrossRef
Blaschke UK, Silberstein J, Muir TW (2000) Protein engineering by expressed protein ligation. Methods Enzymol 328:478–496CrossRef
Borchmann DE, Carberry TP, Weck M (2014) “Bio”-macromolecules: polymer-protein conjugates as emerging scaffolds for therapeutics. Macromol Rapid Commun 35(1):27–43CrossRef
Cheng TL, Cheng CM, Chen BM, Tsao DA, Chuang KH, Hsiao SW, Lin YH, Roffler SR (2005) Monoclonal anti-body-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles. Bioconjug Chem 16:1225–1231CrossRef
Clancy KW, Melvin JA, McCafferty DG (2010) Sortase transpeptidases: insights into mechanism, substrate specificity, and inhibition. Biopolymers 94:385–396CrossRef
Comfort D, Clubb RT (2004 May 1) A comparative genome analysis identifies distinct sorting pathways in gram-positive bacteria. Infect Immun 72(5):2710–22CrossRef
Dawson PE, Kent SB (2000) Synthesis of native proteins by chemical ligation. Annu Rev Biochem 69:923–960CrossRef
Desvaux M, Dumas E, Chafsey I, He’braud M (2006) FEMS Microbiol Lett 256:1–15CrossRef
Dozier JK, Distefano MD (2015) Site-specific PEGylation of therapeutic proteins. Int J Mol Sci 16(10):25831–25864CrossRef
Dramsi S, Trieu-Cuot P, Bierne H (2005) Sorting sortases: a nomenclature proposal for the various sortases of gram-positive bacteria. Res Microbiol 156(3):289–297CrossRef
Garratty G (2004) Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs. Transfus Med Rev 18:245–256CrossRef
Gordon MR et al (2015) Field guide to challenges and opportunities in antibody drug conjugates for chemists. Bioconjug Chem 26:2198–2215CrossRef
Graham ML (2003) Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 55:1293–1302CrossRef
Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2(3):214–221CrossRef
Jackson DY, Burnier J, Quan C, Stanley M, Tom J et al (1994) A designed peptide ligase for total synthesis of ribonuclease A with unnatural catalytic residues. Science 266:243–247CrossRef
Kerwin BA, Chang BS, Gegg CV, Gonnelli M, Li T, Strambini GB (2002) Interactions between PEG and type I soluble tumor necrosis factor receptor: modulation by pH and by PEGylation at the N terminus. Protein Sci 11:1825–1833CrossRef
Kinstler O, Moulinex G, Treheit M, Ladd D, Gegg C (2002) Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 54:477–485CrossRef
Knop K, Hoogenboom R, Fischer D, Schubert US (2010) Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed 49:6288–6308CrossRef
Krug LM, Ragupathi G, Ng KK, Hood C, Jennings HJ, Guo Z, Kris MG, Miller V, Pizzo B, Tyson L, Baez V, Livingston PO (2004) Clin Cancer Res 10:916–923CrossRef
Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW et al (2005) Peginterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis b. N Engl J Med 352:2682–2695CrossRef
Levary DA, Parthasarathy R, Boder ET, Ackerman ME (2011) Protein-protein fusion catalyzed by sortase A. PLoS One 6(4):e18342CrossRef
Li F, Mahato RI (2017) Bioconjugate therapeutics: current progress and future perspective. Mol Pharm 14(5):1321–1324CrossRef
Malik NN (2008) Drug discovery: past, present and future. Drug Discov Today 13(21–22):909–912CrossRef
Maresso AW, Schneewind O (2008) Sortase as a target of anti-infective therapy. Pharmacol Rev 60(1):128–141CrossRef
Marraffini LA, Dedent AC, Schneewind O (2006) Microbiol Mol Biol Rev 70:192–221CrossRef
Mazmanian SK (1999) Staphylococcus aureus Sortase, an enzyme that anchors surface proteins to the cell wall. Science 285:760–763CrossRef
Mazmanian SK, Liu G, Jensen ER, Lenoy E, Schneewind O (2000) Staphylococcus aureus sortase mutants defective in the display of surface proteins and in the pathogenesis of animal infections. Proc Natl Acad Sci U S A 97:5510–5515CrossRef
Mazmanian SK, Ton-That H, Schneewind O (2001) Mol Microbiol 40:1049–1057CrossRef
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER et al (2009) Peginterferon α-2b or α-2a with ribavirin for treatment of hepatitis c infection. N Engl J Med 361:580–593CrossRef
Mero A, Clementi C, Veronese FM, Pasut G (2011) Covalent conjugation of poly (ethylene glycol) to proteins and peptides: strategies and methods. In: Bioconjugation protocols. Humana Press, Totowa, pp 95–129CrossRef
Monfardini C, Schiavon O, Caliceti P et al (1995) A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem 6:62–69CrossRef
Palomares LA, Kuri-Breña F, Ramírez OT (2002) Industrial recombinant protein production. In: The Encyclopedia of Life Support Systems, vol 6. EOLSS Publishers, Oxford. (3.8)
Parthasarathy R, Subramanian S, Boder ET (2007) Sortase a as a novel molecular “stapler” for sequence-specific protein conjugation. Bioconjug Chem 18(2):469–476CrossRef
Pelegri-O’Day EM, Lin E-W, Maynard HD (2014) Therapeutic protein−polymer conjugates: advancing beyond PEGylation. J Am Chem Soc 136(41):14323–14332. PubMed: 25216406CrossRef
Pisal DS, Kosloski MP, Balu-Iyer SV (2010a) Delivery of therapeutic proteins. J Pharm Sci 99(6):2557–2575CrossRef
Pisal DS, Kosloski MP, Balu-Iyer SV (2010b) Delivery of therapeutic proteins. J Pharm Sci 99(6):2557–2575CrossRef
Popp MWL, Ploegh HL (2011) Making and breaking peptide bonds: protein engineering using sortase. Angew Chem Int Ed 50:5024–5032CrossRef
Popp MW, Dougan SK, Chuang TY, Spooner E, Ploegh HL (2011) Sortase-catalyzed transformations that improve the properties of cytokines. Proc Natl Acad Sci U S A 108:3169–3174CrossRef
QI MIDAS MAT Q2 (2016) LCUS$ used for growth figures
QI MIDAS MAT Q4 (2015) ex-manufacturer level pricing, excludes discounts and rebates
Richter AW, Åkerblom E (1983) Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol 70:124–131CrossRef
Roberts MJ, Harris JM (1998) Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy. J Pharm Sci 87(11):1440–1445CrossRef
Sanchez-Garcia L, Martín L, Mangues R, Ferrer-Miralles N, Vázquez E, Villaverde A (2016) Recombinant pharmaceuticals from microbial cells: a 2015 update. Microb Cell Factories 15(1):33CrossRef
Schwartz RS (2004a) Paul Ehrlich’s magic bullets. New Engl J Med 350:1079–1080CrossRef
Schwartz RS (2004b) Paul Ehrlich’s magic bullets. N Engl J Med 350(11):1079–1080CrossRef
Seeberger PH, Werz DB (2007) Synthesis and medical applications of oligosaccharides. Nature 446(7139):1046CrossRef
Sherman MR, Saifer MG, Perez-Ruiz F (2008) PEG-Uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 60:59–68CrossRef
Shimizu T, Ichihara M, Yoshioka Y, Ishida T, Nakagawa S, Kiwada H (2012) Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response. Biol Pharm Bull 35:1336–1342CrossRef
Singh HB, Jha A, Keswani C (eds) (2016) Intellectual property issues in biotechnology. CABI, Wallingford. 304 pages, ISBN-13: 9781780646534
Singh HB, Keswani C, Singh SP (eds) (2019a) Intellectual property issues in microbiology. Springer-Nature, Singapore. 425 pages, ISBN- 9789811374654
Singh HB, Keswani C, Reddy MS, Royano ES, García-Estrada C (2019b) Secondary metabolites of plant growth promoting Rhizomicroorganisms: discovery and applications. Springer-Nature, Singapore. 392 pages, ISBN- 978-981-13-5861-6CrossRef
Sroda K, Rydlewski J, Langner M, Kozubek A, Grzybek M, Sikorski AF (2005) Repeated injections of PEG-PE liposomes generate anti- PEG antibodies. Cell Mol Biol Lett 10:37–47
Sundy JS, Ganson NJ, Scarlett E, Rehrig CD, Huang W, Hershfield MS (2007) Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 56:1021–1028. PubMed: 17328081CrossRef
Tang L, Persky AM, Hochhaus G, Meibohm B (2004) Pharmacokinetic aspects of biotechnology products. J Pharm Sci 93(9):2184–2204CrossRef
Tegnér F (2015) Optimization of a PEGylation process A combined reaction and separation with size exclusion reaction chromatography. Department of Chemical Engineering Lund University May 2015
Ton-That H, Marraffini LA, Schneewind O (2004) Biochim Biophys Acta 1694:269–278CrossRef
Van Vught R, Pieters RJ, Breukink E (2014) Site-specific functionalization of proteins and their applications to therapeutic antibodies. Comput Struct Biotechnol J 9(14):e201402001CrossRef
Verez-Bencomo V, Fernandez-Santana V, Hardy E, Toledo ME, Rodríguez MC, Heynngnezz L, Rodriguez A, Baly A, Herrera L, Izquierdo M, Villar A (2004) A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type B. Science 305(5683):522–525CrossRef
Veronese FM (2001) Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 22:405–417CrossRef
Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451–1458. PubMed: 16243265CrossRef
Veronese FM, Mero A, Caboi F, Sergi M, Marongiu C, Pasut G (2007) Bioconjug Chem 18(6):1824–1830CrossRef
Witte MD, Theile CS, Wu T, Guimaraes CP, Blom AEM, Ploegh HL (2013) Production of unnaturally linked chimeric proteins using a combination of sortase-catalyzed transpeptidation and click chemistry. Nat Protoc 8:1808–1819CrossRef
Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M et al (2006) Peginterferon α-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis b. Hepatology 44:675–684CrossRef
Zhang F, Liu M-r, Wana H-t (2014) Discussion about several potential drawbacks of PEGylated therapeutic proteins. Biol Pharm Bull 37(3):335–339CrossRef
Zong Y, Bice TW, Ton-That H, Schneewind O, Narayana SV (2004) Crystal structures of Staphylococcus aureus sortase A and its substrate complex. J Biol Chem 279:31383–31389CrossRef
Metadaten
Titel
Conjugated Recombinant Proteins as Emerging New Drugs
verfasst von
Nasir Mahmood
Sarah Bushra Nasir
Kathleen Hefferon
Copyright-Jahr
2020
Verlag
Springer Singapore
Buch
Bioeconomy for Sustainable Development

Print ISBN: 978-981-13-9430-0

Electronic ISBN: 978-981-13-9431-7

Copyright-Jahr: 2020

DOI
https://doi.org/10.1007/978-981-13-9431-7_18